Subscribe
shutterstock_1635596416_sundry_photography
Sundry Photography / Shutterstock.com
1 April 2021BiotechnologyBenjamin Pelletier

The uncertain future of antibody claims

A long string of decisions from the US Court of Appeals for the Federal Circuit has undermined support for purely functional antibody epitope claims through the written description and enablement requirements of 35 USC §112.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025
Americas
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
6 May 2025
Americas
Why US patent reform is ‘essential’ for US economic prosperity and security
29 April 2025
Europe
Meril v Edwards: Harmonisation of obviousness at the UPC and the EPO
24 April 2025
Americas
WIPR Diversity & Inclusion reveals Top 100 People in IP for 2025
24 April 2025
Big Pharma
AstraZeneca unit faces class-action suit over alleged Soliris monopoly
17 April 2025

More on this story

Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

More on this story

Americas
Haynes Boone hires top biotech patent lawyer
19 July 2022   New partner boosts firm’s biotech practice | Move forms part of life sciences expansion | Role based at Washington, DC office.
Big Pharma
Sanofi and C4X in $493m licensing deal
13 April 2021   UK company C4X Discovery has agreed an exclusive licensing deal with Sanofi worth a potential €414 million, which will see the French pharmaceutical company develop anti-inflammatory therapies.
Americas
Amgen antibody patents ‘too broad’, says Fed Circuit
16 February 2021   The US Court of Appeals for the Federal Circuit has invalidated two Amgen antibody patents, finding that their functional claims were too broad.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
LSPN: Counsel grapple with AI’s impact on training and critical thinking
LSPN: Trump's policy storm causing chaos and confusion
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB
Novartis settles with licensee of blood cancer therapy day before trial
Foley adds five-partner team from Perkins Coie and K&L Gates
Judge denies Pfizer and BioNTech bid to see off COVID-19 vaccine suit